- Trial Phase
- Phase 1b
- Time to Market
- At least 4-6 years if Phase 1b/2 and Phase 3 are successful; no PDUFA or registration-track trial yet.
- Why 9/10
- NXP900 is effectively Nuvectis' only pipeline asset after NXP800 was discontinued in July 2025. The next hard catalyst is the preliminary Phase 1b data readout expected in summer 2026 (imminent within weeks). With a ~$250-275M market cap, cash of only $25M, and no other late-stage programs, this readout is a make-or-break binary for the stock — hence the score of 9.
The summer 2026 Phase 1b preliminary readout is the defining event for NVCT. Positive data showing early efficacy signals in biomarker-selected patients could trigger a major re-rating; negative data or weak enrollment updates would leave a cash-constrained single-asset company with no backup, risking severe downside. The stock is technically overbought (RSI 91.3) with a short volume ratio of ~68% on heavy volume, suggesting a volatile binary event.
Price Chart
Executive Summary
NXP900 is Nuvectis Pharma's lead (and now sole) clinical-stage asset — an oral SRC/YES1 kinase inhibitor with a novel "type 1.5" mechanism that differentiates it from older SRC inhibitors like dasatinib. The drug has completed Phase 1a dose-escalation safely in 33 patients and is now in Phase 1b testing as monotherapy and in combination with osimertinib for EGFR-mutant NSCLC. After the failure and discontinuation of sister drug NXP800 in ovarian cancer, Nuvectis is now a de facto single-asset company with ~$25M cash and a $150M shelf offering on file. Analyst consensus is strongly bullish (10 Buy vs 1 Hold, mean PT ~$29), and major institutions (Fidelity, Wells Fargo, Morgan Stanley, Bank of America) have accumulated positions. The pivotal near-term catalyst is the preliminary Phase 1b readout expected in summer 2026 — a binary event that could either validate the drug's promise or leave the company struggling for credibility and capital.
How It Works
NXP900 is a pill that targets a family of proteins called SRC kinases, which act like "on switches" that tell cancer cells to grow and spread. Unlike older drugs that only partially block these switches, NXP900 uses a unique "lock" mechanism — it binds to the SRC protein in its naturally inactive, folded-up shape and locks it there. This prevents both the protein's enzymatic activity and its ability to physically interact with other cancer-promoting proteins, providing a more complete shutdown of the pathway. It is highly selective, meaning it hits its target without causing as many off-target side effects as older SRC inhibitors like dasatinib (Sprycel).
Trial Status
Phase 1a dose-escalation completed (33 patients, 20-300 mg daily, acceptable safety, robust pharmacodynamic response at ≥150 mg/day). Phase 1b monotherapy and combination (with osimertinib in NSCLC) studies initiated August 2025 and are actively enrolling. A drug-drug interaction study in healthy volunteers was completed successfully. Preliminary Phase 1b data readout expected summer 2026. Multiple preclinical posters presented at AACR 2025 and AACR-NCI-EORTC 2025.
The Two-Sided Case
Upcoming Catalysts
- Preliminary Phase 1b data readout expected summer 2026 (imminent, likely July-August) — the single most important near-term catalyst.
- AACR 2026 presentations (April 2026 abstracts on NXP900 synergy with KRAS inhibitors and other preclinical data).
- Potential initiation of the combination arm of Phase 1b (NXP900 + osimertinib in NSCLC) — expected by year-end 2025 per Q3 2025 report; likely already underway.
- Subsequent clinical data at medical conferences (e.g., ESMO, AACR-NCI-EORTC) throughout 2026.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Nuvectis Pharma, Inc. 424B5 NVCT ·Originating report